APA (7th ed.) Citation

Shi, H., Guo, J., Fan, W., Li, Y., Huang, R., Dong, Q., . . . Wang, J. (2026). A phase II study evaluating pharmacokinetics and dosimetry of 177Lu-PSMA-617 radioligand therapy in Chinese participants with progressive metastatic castration-resistant prostate cancer. EJNMMI Research, 16(1), 1. https://doi.org/10.1186/s13550-026-01401-3

Chicago Style (17th ed.) Citation

Shi, Hongcheng, et al. "A Phase II Study Evaluating Pharmacokinetics and Dosimetry of 177Lu-PSMA-617 Radioligand Therapy in Chinese Participants with Progressive Metastatic Castration-resistant Prostate Cancer." EJNMMI Research 16, no. 1 (2026): 1. https://doi.org/10.1186/s13550-026-01401-3.

MLA (9th ed.) Citation

Shi, Hongcheng, et al. "A Phase II Study Evaluating Pharmacokinetics and Dosimetry of 177Lu-PSMA-617 Radioligand Therapy in Chinese Participants with Progressive Metastatic Castration-resistant Prostate Cancer." EJNMMI Research, vol. 16, no. 1, 2026, p. 1, https://doi.org/10.1186/s13550-026-01401-3.